333 related articles for article (PubMed ID: 22846154)
1. Experimental efficacy of mycophenolate mofetil implant on high-risk corneal allograft rejection and its biocompatibility in the anterior chamber of rabbits.
Xin M; Wang T; Shi W; Wu X
J Ocul Pharmacol Ther; 2012 Dec; 28(6):609-17. PubMed ID: 22846154
[TBL] [Abstract][Full Text] [Related]
2. [Sustained rapamycin drug delivery system in prevention of high risk corneal allograft rejection and neovascularization in rabbits].
Gao H; Shi WY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):6-11. PubMed ID: 16638273
[TBL] [Abstract][Full Text] [Related]
3. [Implantation of FK506 drug delivery system into the anterior chamber for inhibiting corneal rejection in high risk rabbit corneal allograft].
Shi WY; Liu T; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):299-304. PubMed ID: 16762204
[TBL] [Abstract][Full Text] [Related]
4. [Prolongation of corneal allograft survival in mice with a cyclosporine drug delivery system implant].
Shi W; Xie L; Wang S
Zhonghua Yan Ke Za Zhi; 2002 Aug; 38(8):502-5. PubMed ID: 12410993
[TBL] [Abstract][Full Text] [Related]
5. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits.
Shi W; Gao H; Xie L; Wang S
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3339-44. PubMed ID: 16877400
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment.
Zhang T; Li Z; Liu T; Li S; Gao H; Wei C; Shi W
PLoS One; 2018; 13(5):e0196571. PubMed ID: 29734357
[TBL] [Abstract][Full Text] [Related]
7. Experimental study on the effect of cyclosporine A drug delivery system implanted in anterior chamber on high-risk corneal graft rejection.
Xie L; Shi W; Wang Z; Liu Z
Zhonghua Yan Ke Za Zhi; 2002 Jul; 38(7):422-5. PubMed ID: 12411004
[TBL] [Abstract][Full Text] [Related]
8. [Combined rapamycin eye drop in nanometer vector and poly (lactic acid) wafers of cyclosporine A effectively prevents high-risk corneal allograft rejection in rabbits].
Jiang W; Sun HM; Li XR; Yuan XB; Wang YQ; Zhang SX; Tian EJ; Yuan JQ
Zhonghua Yan Ke Za Zhi; 2009 Jun; 45(6):550-5. PubMed ID: 19957680
[TBL] [Abstract][Full Text] [Related]
9. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.
Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197
[TBL] [Abstract][Full Text] [Related]
10. Survival of corneal allografts following topical treatment with the immunomodulator mycophenolate mofetil.
Bertelmann E; de Ruijter M; Gong N; Knapp S; Pleyer U
Ophthalmologica; 2010; 224(1):38-41. PubMed ID: 19672124
[TBL] [Abstract][Full Text] [Related]
11. The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits.
Wu XG; Xin M; Yang LN; Shi WY
J Pharm Sci; 2011 Apr; 100(4):1350-61. PubMed ID: 24081470
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial.
Reis A; Reinhard T; Voiculescu A; Kutkuhn B; Godehardt E; Spelsberg H; Althaus C; Sundmacher R
Br J Ophthalmol; 1999 Nov; 83(11):1268-71. PubMed ID: 10535855
[TBL] [Abstract][Full Text] [Related]
13. A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study.
Shi W; Chen M; Xie L; Liu M; Gao H; Wang T; Wu X; Zhao J
Ophthalmology; 2013 Apr; 120(4):695-702. PubMed ID: 23246118
[TBL] [Abstract][Full Text] [Related]
14. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model.
Birnbaum F; Schwartzkopff J; Scholz C; Reis A; Reinhard T
Eye (Lond); 2007 Dec; 21(12):1516-23. PubMed ID: 17401326
[TBL] [Abstract][Full Text] [Related]
15. Prevention of corneal allograft rejection in a mouse model of high risk recipients.
Vítová A; Filipec M; Zajícová A; Krulová M; Holán V
Br J Ophthalmol; 2004 Oct; 88(10):1338-42. PubMed ID: 15377562
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study.
Birnbaum F; Mayweg S; Reis A; Böhringer D; Seitz B; Engelmann K; Messmer EM; Reinhard T
Eye (Lond); 2009 Nov; 23(11):2063-70. PubMed ID: 19151659
[TBL] [Abstract][Full Text] [Related]
17. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.
Reinhard T; Reis A; Böhringer D; Malinowski M; Voiculescu A; Heering P; Godehardt E; Sunmacher R
Graefes Arch Clin Exp Ophthalmol; 2001 Jun; 239(5):367-72. PubMed ID: 11482341
[TBL] [Abstract][Full Text] [Related]
18. Effect of a cyclosporine A delivery system in corneal transplantation.
Xie L; Shi W; Wang Z; Bei J; Wang S
Chin Med J (Engl); 2002 Jan; 115(1):110-3. PubMed ID: 11930640
[TBL] [Abstract][Full Text] [Related]
19. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model.
Reis A; Reinhard T; Sundmacher R; Braunstein C; Godehardt E
Br J Ophthalmol; 1998 Jun; 82(6):700-3. PubMed ID: 9797676
[TBL] [Abstract][Full Text] [Related]
20. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model.
Shi W; Chen M; Xie L
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1691-7. PubMed ID: 17541621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
